Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KITPRNewsWire • 05/06/24
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 05/03/24
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%Zacks Investment Research • 04/23/24
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 04/05/24
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/02/24
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/26/24
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdatePRNewsWire • 03/26/24
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update CallPRNewsWire • 03/19/24
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)PRNewsWire • 02/22/24
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024PRNewsWire • 01/31/24
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select ConferencePRNewsWire • 01/23/24
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™PRNewsWire • 01/16/24
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma ResearchPRNewsWire • 12/07/23
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market ExpectsSeeking Alpha • 11/17/23